Sodium phenylacetate modulates the synthesis of autocrine and paracrine growth factors secreted by breast cancer cell lines

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2657-2661

  Thibout, D ^a   Di Benedetto, M ^a   Kraemer, M ^a   Sainte Catherine, O ^a   Derbin, C ^a   Crepin M ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Breast cancer; Growth factors; Sodium phenylacetate

Indexed keywords

ACECAINIDE; GROWTH FACTOR;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; FEMALE; GROWTH SUBSTANCES; HUMANS; KINETICS; MICE; PHENYLACETATES; PRECANCEROUS CONDITIONS; TUMOR CELLS, CULTURED;

EID: 0031866541     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Sporn MB and Roberts AB: Autocrine growth factors and cancer. Nature 313: 745-747, 1985.
2. Cross M and Dexter TM: Growth factors in developpment, tranformation, and tumorigenesis. Cell 64: 271-280, 1991.
3. Cullen KJ and Lippman ME: Stromal-epithelial interactions in breast cancer. Cancer Tret Res 61: 413-431, 1992.
4. Souttou B, Hamelin R and Crépin M: FGF2, as an autocrine growth factor for immortal human breast epithelial cells. Cell Growth and Diff 5: 615-623, 1994.
5. Bronzert K, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB and Lippman ME: Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sei USA 84: 5763-5767, 1987.
6. Knabbe C, Wakefield L, Flanders K, Kasid A, Derynck R, Lippman ME and Dickson RB: Evidence that TGF beta is a hormonally regulated negative growth factor in human breast cancer. Cell 48: 417-428, 1987.
7. Gorsh SM: Immunohistochemical staining for transforming growth factor beta associates with disease progression in human breast cancer. Cancer Res 52: 6949-6952, 1992.
8. Samuel SK, Hurta RAR, Kondaiah P, Khalil N, Turley EA, Wright JA and Greenberg AH: Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF. Embo J 11: 1599-1605, 1992.
9. Artaga CL, Carty-Dugger T, Moses HL, Hurd SD and Pietenpol JA: Transforming Growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth and Diff 4(3): 193-201, 1993.
10. Sandler M, Ruthven CRJ, Goodwin BL,Less A and Stern GM: Phenylacetic acid in human body fluids, high correlation between plasma and cerebrospinal fluid concentrations values. J Neurol Neurosurg Psychiatry 45: 366-368, 1982.
11. Samid D Shack S and Sherman, LT: Phenylacetate: a novel nontoxic inducer of tumor cell differenciation. Cancer Res 52: 1988-1992, 1992.
12. Samid D, Yeh A and Prasanna P: Induction of erythroid differenciation and fetal hemoglobin production in human neuroblastoma cells induced by sodium phenylacetate. Cancer Lett 70: 41-48, 1993.
13. Cinatl JJ, Cinatl J, Mainke M, Weibflog A, Rabenau H, Kommhuber B and Doerr HW: In vitro differenciation of human neuroblastoma cells induced by sodium phenylacetate. Cancer Lett 70: 41-48, 1993.
14. Cinatl JJ, Cinatl J, Herneiz P, Rabenau H, Novak M, Benda R, Gümbel H, Kornhuber B and Doerr H-W: Induction of mitogenic differenciation in a human rhabdomyosarcoma cell line by phenylacetate. Cancer Lett 78: 41-48, 1994.
15. Sidell N, Wada R, Han G, Chang B, Shack S, Moore T and Samid D: Phenylacetate synergizes with retinoic acid in including the differenciation of human neuroblastoma cells. Int J Cancer 60: 507-514, 1995.
16. Adam L, Crépin M, Savin C, Israel L: Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF-7ras cells in vitro and in nude mice. Cancer Res 55: 5156, 1995a.
17. Adam L, Crépin M, Israel L: Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras by sodium phenylacetate and tamoxifen combinaison. Cancer Res 57: 1023-1029, 1995b.
18. Thibault A;, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins A C, Weinberger MS, Headlee DJ, McCall NA, Samid D and Myers CE: A phase I pharmacokinetic study of intraveinous phenylacetate in patients with cancer. Cancer Res 54: 1690-1694, 1994.
19. Neish WJP: Phenylacetic acid as a potential therapeutic agent for the treatment of human cancer. Experentia (Basel) 27: 860, 1971.
20. Ferrandina G, Melichar B, Loercher A, Verschraegen CF, Kudelka AP, Creighton L, Scambia G, Kavanagh JJ, Abbruzzese JL and Freedman RS: Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res 57: 4309-4315, 1997.
21. Samid D, Ram Z, Hudgins R, Shack S, Liu L, Walbridge S, Oldfield EH: Selective activity of phenylacetate against malignant gliomas resemblance to fetal brain damage in phenylketonuria. Cancer Res 54: 891-895, 1994.
22. Shack S, Chen LC, Miller AC, Danesi R and Samid D: Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Int J Cancer 63: 124-129, 1995.
23. Hudgins WR, Shack S, Myers CE and Samid D: Cytostatic activity of phenylcetate and derivatives against tumor cells. Biochem Pharmacol 50: 1273-1279, 1995.
24. Danest R, Nardini D, Basolo F, Deltacca M, Samid D and Myers CE: Pnenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCAP prostate cancer cells tranfected with the T24 Ha-RAS oncogene. Mol Pharmacol 49: 972-979, 1996.
25. Sommers CL, Papageorge A, Wilding G, Gelmann EP: Growth properties and tumorogenesis of MCF-7 cells transfected with isogenic mutant of ras H. Cancer Res 50: 67-71, 1990.
26. Liu JF, Issad T, Chevet E, Ledoux D, Courty J, Caruelle JP, Barritault D, Crepin M and Bertin B. Manuscript in preparation.
27. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG and Simons JW: Phenylbutyrate is more potent than phenylacetate. Clin Res 2: 379-387, 1996.
28. Stockhammer G, Manley GT, Johnson R, Rosenblum MK, Samid D and Lieberman FS: Inhibition of proliferation and induction of differenciation in medulloblastoma and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 83: 672-681, 1995.